Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | KLK7 | P49862 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320293 | 0.95 | SYK (0.57) | SYKKLK7KLK5MAPTATM | |
| SCHEMBL14320294 | 0.95 | SYK (0.57) | SYKKLK7KLK5MAPTATM | |
| SCHEMBL12294552 | 0.90 | SYK (0.48) | SYKKLK7KLK5MAPTATM | |
| SCHEMBL4857149 | 0.87 | MAPT (0.58) | SYKKLK7KLK5MAPTCTSS | |
| SCHEMBL2265883 | 0.87 | SYK (0.54) | SYKKLK7KLK5ATMCTSS | |
| SCHEMBL2265891 | 0.87 | SYK (0.54) | SYKKLK7KLK5ATMCTSS | |
| SCHEMBL16124431 | 0.86 | MAPT (0.60) | KLK7KLK5MAPTCTSSCTSL | |
| SCHEMBL13289745 | 0.86 | SYK (0.56) | SYKKLK7KLK5MAPTCTSS | |
| SCHEMBL5996732 | 0.85 | CTSK (0.61) | KLK7KLK5MAPTCTSSCTSL | |
| SCHEMBL12667695 | 0.85 | MAPT (0.59) | KLK7KLK5MAPTCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329724-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED | 2012-12-27 | — | — | US | disclosed |
| WO-2011104649-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED (GB) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207654-A1 | PEPTIDE ANALOGUES | PFIZER INC. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329724-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | SYK 3794/4885KLK7 686/4885KLK5 825/4885 |
| US-20110207654-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | SYK 3794/4885KLK7 686/4885KLK5 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.